Atrium Therapeutics Provides Inducement Grants to New Employee Under Nasdaq Rule
Atrium Therapeutics, Inc., trading on Nasdaq under the symbol RNA, has officially announced the award of inducement grants on September 20, 2026. This decision aligns with the company's commitment to attracting highly qualified individuals by offering substantial employment incentives. Specifically, one non-executive newly hired individual will receive these awards as part of Atrium's 2026 Employment Inducement Incentive Award Plan.
The inducement grants consist of non-qualified stock options and restricted stock units. The employee will receive stock options allowing them to purchase 13,500 shares of the company’s common stock, with a designated exercise price of $8.95 per share. This price reflects the closing stock value from the Nasdaq on the company’s last trading day before the grant was activated. The awarded stock options will be subject to a vesting schedule in which 25% will become available on the first anniversary of the grant date, while the remaining shares will vest in substantially equal monthly installments over the subsequent three years, contingent upon the employee continuing their service with the company.
In addition to the stock options, the employee is also being granted restricted stock units for a total of 6,750 shares. These too will vest in accordance with a similar timeline; 25% on the first anniversary of the grant date, followed by three equal annual installments, again subject to the employee's ongoing service.
This initiative has received backing from the Human Capital Management Committee of Atrium’s Board of Directors, which is comprised entirely of independent directors, ensuring the process adheres to the guidelines outlined in Nasdaq Listing Rule 5635(c)(4). By offering these inducement grants, Atrium Therapeutics aims to foster a competitive work environment, attracting top-tier talent that aligns with its innovative goals and objectives.
About Atrium Therapeutics, Inc.:
Atrium Therapeutics is at the forefront of biopharmaceutical development, focusing on innovative RNA therapeutics aimed at cardiomyopathies. The company has recently secured FDA clearance for its Investigational New Drug (IND) application for ATR 1072, targeting PRKAG2 syndrome. This advancement marks a significant milestone in the company’s mission to transform the standard of care in precision cardiology. With a pipeline that not only includes ATR 1072 but also extends to ATR 1086 for PLN cardiomyopathy and additional research targets, Atrium Therapeutics demonstrates a commitment to addressing rare and genetically driven cardiac diseases through its unique delivery platform designed by Avidity Biosciences, Inc.
Atrium continues to seek breakthroughs that harness the potential of RNA therapeutics, with a focus on precision targeting that aims to change the way cardiac conditions are treated and managed. For more details on Atrium’s offerings and their ongoing research, please visit Atrium Therapeutics' website and follow their updates on LinkedIn.
The inducement grants consist of non-qualified stock options and restricted stock units. The employee will receive stock options allowing them to purchase 13,500 shares of the company’s common stock, with a designated exercise price of $8.95 per share. This price reflects the closing stock value from the Nasdaq on the company’s last trading day before the grant was activated. The awarded stock options will be subject to a vesting schedule in which 25% will become available on the first anniversary of the grant date, while the remaining shares will vest in substantially equal monthly installments over the subsequent three years, contingent upon the employee continuing their service with the company.
In addition to the stock options, the employee is also being granted restricted stock units for a total of 6,750 shares. These too will vest in accordance with a similar timeline; 25% on the first anniversary of the grant date, followed by three equal annual installments, again subject to the employee's ongoing service.
This initiative has received backing from the Human Capital Management Committee of Atrium’s Board of Directors, which is comprised entirely of independent directors, ensuring the process adheres to the guidelines outlined in Nasdaq Listing Rule 5635(c)(4). By offering these inducement grants, Atrium Therapeutics aims to foster a competitive work environment, attracting top-tier talent that aligns with its innovative goals and objectives.
About Atrium Therapeutics, Inc.:
Atrium Therapeutics is at the forefront of biopharmaceutical development, focusing on innovative RNA therapeutics aimed at cardiomyopathies. The company has recently secured FDA clearance for its Investigational New Drug (IND) application for ATR 1072, targeting PRKAG2 syndrome. This advancement marks a significant milestone in the company’s mission to transform the standard of care in precision cardiology. With a pipeline that not only includes ATR 1072 but also extends to ATR 1086 for PLN cardiomyopathy and additional research targets, Atrium Therapeutics demonstrates a commitment to addressing rare and genetically driven cardiac diseases through its unique delivery platform designed by Avidity Biosciences, Inc.
Atrium continues to seek breakthroughs that harness the potential of RNA therapeutics, with a focus on precision targeting that aims to change the way cardiac conditions are treated and managed. For more details on Atrium’s offerings and their ongoing research, please visit Atrium Therapeutics' website and follow their updates on LinkedIn.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.